Ensitrelvir

Ensitrelvir
Clinical data
Trade names	Xocova
Other names	S-217622
Routes of; administration	By mouth
ATC code	J05AE11 (WHO) ;
Legal status
Legal status	JP: Rx-only;
Pharmacokinetic data
Elimination half-life	42–48 hours
Identifiers
	IUPAC name 1-(2,4,5-Trifluorobenzyl)-3-[(1-methyl-1H-1,2,4-triazol-3-yl)methyl]-(6E)-6-[(6-chloro-2-methyl-2H-indazol-5-yl)imino]-1,3,5-triazinane-2,4-dione;
CAS Number	2647530-73-0; 2757470-18-9;
PubChem CID	162533924;
DrugBank	DB18834;
ChemSpider	115007411;
UNII	PX665RAA3H;
KEGG	D12353;
Chemical and physical data
Formula	C22H17ClF3N9O2
Molar mass	531.88 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES Cn1cnc(CN2C(=O)N(Cc3cc(F)c(F)cc3F)C(=N\c3cc4cn(C)nc4cc3Cl)\NC2=O)n1;
	InChI InChI=1S/C22H17ClF3N9O2/c1-32-7-12-4-18(13(23)5-17(12)30-32)28-20-29-21(36)35(9-19-27-10-33(2)31-19)22(37)34(20)8-11-3-15(25)16(26)6-14(11)24/h3-7,10H,8-9H2,1-2H3,(H,28,29,36); Key:QMPBBNUOBOFBFS-UHFFFAOYSA-N;

Ensitrelvir, sold under the brand name Xocova is an antiviral medication used as a treatment for COVID-19. It was developed by Shionogi in partnership with Hokkaido University and acts as an orally active 3C-like protease inhibitor. It is taken by mouth.

The most common adverse events include transient decreases in high-density lipoprotein and increased blood triglycerides.